LONDON MARKET CLOSE: Stocks mixed amid tech earnings, Fed fallout
(Alliance News) - Stock prices in London closed mostly higher on Thursday, as investors digested the US Federal Reserve's Wednesday decision to stand pat on interest rates. Read More
| Price | 1,857.50p on 30-01-2026 at 13:03:00 |
|---|---|
| Change | 5.50p 0.3% |
| Buy | 1,857.50p |
| Sell | 1,857.00p |
| Last Trade: | Unknown 0.00 at 1,857.50p |
| Day's Volume: | 1,545,339 |
| Last Close: | 1,852.00p |
| Open: | 1,836.00p |
| ISIN: | GB00BN7SWP63 |
| Day's Range | 1,823.00p - 1,858.50p |
| 52wk Range: | 1,242.50p - 1,909.50p |
| Market Capitalisation: | £74.93b |
| VWAP: | 1,843.26281p |
| Shares in Issue: | 4.03b |
Glaxosmithkline (GSK) Latest Trades |
||||
| Buy/Sell | Volume | Trade Prc | Trade Type | Trade Time |
|---|---|---|---|---|
| Unknown* | 0 | 1,857.50p | SI Trade |
13:03:00 - 30-Jan-26 |
| Buy* | 460 | 1,857.50p | Automatic Execution |
13:03:00 - 30-Jan-26 |
| Buy* | 100 | 1,857.50p | Automatic Execution |
13:03:00 - 30-Jan-26 |
| Unknown* | 0 | 1,857.50p | SI Trade |
13:02:50 - 30-Jan-26 |
| Sell* | 45 | 1,857.184p | Ordinary |
13:02:47 - 30-Jan-26 |
| Sell* | 1 | 1,857.00p | SI Trade |
13:01:58 - 30-Jan-26 |
| Sell* | 140 | 1,857.192p | Ordinary |
13:01:29 - 30-Jan-26 |
| Unknown* | 0 | 1,857.50p | OTC Trade |
13:00:47 - 30-Jan-26 |
| Unknown* | 0 | 1,857.50p | OTC Trade |
13:00:46 - 30-Jan-26 |
| Buy* | 10 | 1,857.50p | Ordinary |
13:00:45 - 30-Jan-26 |
Glaxosmithkline (GSK) Regulatory News |
||
| Date | Source | Headline |
|---|---|---|
| 26th Jan 2026 7:00 am | RNS | European Commission approves Arexvy for adults 18+ |
| 20th Jan 2026 7:05 am | RNS | GSK to acquire RAPT Therapeutics |
| 20th Jan 2026 7:00 am | RNS | Agreement on changes to ViiV minority shareholding |
| 16th Jan 2026 3:30 pm | RNS | Director/PDMR Shareholding |
| 15th Jan 2026 3:30 pm | RNS | Director/PDMR Shareholding |
| 13th Jan 2026 3:30 pm | RNS | Director/PDMR Shareholding |
| 7th Jan 2026 7:05 am | RNS | EC approval of Shingrix PFS |
| 7th Jan 2026 7:00 am | RNS | Positive phase 3 data for GSK's bepirovirsen |
| 6th Jan 2026 7:00 am | RNS | Exdensur approved in Japan |
| 5th Jan 2026 3:30 pm | RNS | Director/PDMR Shareholding |